Share Twitter LinkedIn Facebook Email Andrew Krivoshik, MD of @AstellasUS explains insights on EV-103 enfortumab vedotin plus pembrolizumab that was presented at ESMO. #ESMO2019 Advertisement
FDA Approves INLEXZOโข / Gemcitabine Intravesical: A Breakthrough for Bladder Cancer Treatment Bladder 4 Mins Read
FDA Approves New Bladder Cancer Therapy: A Look at Anktiva Nogapendekin Alfa Inbakicept-pmln Bladder 4 Mins Read
